Cost-effectiveness of insulin detemir versus NPH for type I diabetes patients in an Italian setting. A meta-analysis

被引：0

作者：

Aristides, M. ^{[1
]}

Kotchie, R. ^{[1
]}

Nielsen, S. ^{[2
]}

Aagren, M. ^{[2
]}

Valentine, W. J. ^{[3
]}

Goodall, G. ^{[3
]}

机构：

[1] IMS Hlth, London, England

[2] Novo Nordisk AS, Virum, Denmark

[3] IMS Hlth, Basel, Switzerland

来源：

VALUE IN HEALTH | 2007年 / 10卷 / 06期

关键词：

D O I：

10.1016/S1098-3015(10)64968-6

中图分类号：

F [经济];

学科分类号：

02 ;

摘要：

引用

页码：A260 / A260

页数：1

共 50 条

[1] Cost-effectiveness of insulin detemir versus NPH for type I diabetes patients in a German setting. A modeling evaluation based upon results from a meta-analysis
Kotchie, R.
Scheijbeler, H.
Aagren, M.
Nielsen, S.
Valentine, W. J.
Goodall, G.
[J]. VALUE IN HEALTH, 2007, 10 (06) : A222 - A222
[2] Cost-effectiveness of detemir versus NPH for type I diabetes patients treated with basal-bolus therapy in a Belgium setting. A modeling evaluation based on results from a meta-analysis of three clinical trials
Scheilbeler, H.
Aagren, M.
Nielsen, S.
Goodall, G.
Kotchie, R.
Valentine, W. J.
[J]. VALUE IN HEALTH, 2007, 10 (06) : A261 - A261
[3] Cost-effectiveness analysis of insulin detemir compared to NPH insulin in patients with type-2 diabetes in the United Kingdom
Smith, I
Palmer, AJ
Roze, S
Kennedy-Martin, T
[J]. VALUE IN HEALTH, 2004, 7 (06) : 735 - 736
[4] Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus in the Canadian payer setting: modeling analysis
Tunis, Sandra L.
Minshall, Michael E.
Conner, Christopher
McCormick, John I.
Kapor, Jovana
Yale, Jean-Francois
Groleau, Danielle
[J]. CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (05) : 1273 - 1284
[5] CLINICAL AND COST OUTCOMES OF TREATMENT WITH INSULIN GLARGINE VERSUS INSULIN DETEMIR IN INSULIN NAIVE TYPE 2 DIABETES PATIENTS: COST-EFFECTIVENESS ANALYSIS IN THE KAZAKHSTAN SETTING
Kostyuk, A.
Akanov, A.
Almadiyeva, A.
[J]. VALUE IN HEALTH, 2016, 19 (03) : A203 - A204
[6] Cost-effectiveness of detemir based basal-bolus therapy versus NPH for type 1 diabetes in a Spanish setting
Ray, J. A.
Valentine, W. J.
Goodall, G.
Aagren, M.
Kotchie, R. W.
[J]. DIABETOLOGIA, 2007, 50 : S428 - S428
[7] SHORT-TERM COST-EFFECTIVENESS ANALYSIS OF INSULIN DETEMIR VERSUS INSULIN NEUTRAL PROTAMINE HAGEDORN (NPH) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS IN SPAIN
Ramirez de Arellano, A.
Morales, C.
De Luis, D.
Ferrario, M. G.
Lizan, L.
[J]. VALUE IN HEALTH, 2014, 17 (07) : A343 - A343
[8] SHORT-TERM COST-EFFECTIVENESS OF INSULIN DETEMIR VERSUS NPH INSULIN IN INSULIN-NAIVE SUBJECTS WITH TYPE 2 DIABETES IN SWEDEN
Ridderstrale, M.
Ericsson, A.
Jensen, M. M.
[J]. VALUE IN HEALTH, 2011, 14 (07) : A480 - A480
[9] Cost-effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Portugal
Cardoso, Cristina
Ramirez de Arellano, Antonio
Prades, Miriam
Lizan, Luis
[J]. JOURNAL OF DIABETES & METABOLISM, 2016, 7 (03)
[10] Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain
Morales, Cristobal
de Luis, Daniel
Ramirez de Arellano, Antonio
Giovanna Ferrario, Maria
Lizan, Luis
[J]. DIABETES THERAPY, 2015, 6 (04) : 593 - 610

← 1 2 3 4 5 →